- Home
- AQB vs ENVB Comparison
AQB vs ENVB Comparison
Compare AQB & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- ENVB
- Stock Information
- Founded
- AQB 1991
- ENVB 1994
- Country
- AQB United States
- ENVB United States
- Employees
- AQB N/A
- ENVB N/A
- Industry
- AQB
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- ENVB Health Care
- Exchange
- AQB Nasdaq
- ENVB Nasdaq
- Market Cap
- AQB 2.9M
- ENVB 3.1M
- IPO Year
- AQB N/A
- ENVB N/A
- Fundamental
- Price
- AQB $0.82
- ENVB $1.29
- Analyst Decision
- AQB
- ENVB Strong Buy
- Analyst Count
- AQB 0
- ENVB 1
- Target Price
- AQB N/A
- ENVB $10.00
- AVG Volume (30 Days)
- AQB 139.7K
- ENVB 225.8K
- Earning Date
- AQB 08-05-2025
- ENVB 08-11-2025
- Dividend Yield
- AQB N/A
- ENVB N/A
- EPS Growth
- AQB N/A
- ENVB N/A
- EPS
- AQB N/A
- ENVB N/A
- Revenue
- AQB N/A
- ENVB N/A
- Revenue This Year
- AQB N/A
- ENVB N/A
- Revenue Next Year
- AQB N/A
- ENVB N/A
- P/E Ratio
- AQB N/A
- ENVB N/A
- Revenue Growth
- AQB N/A
- ENVB N/A
- 52 Week Low
- AQB $0.47
- ENVB $1.01
- 52 Week High
- AQB $1.94
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- AQB 49.12
- ENVB 45.37
- Support Level
- AQB $0.72
- ENVB $1.18
- Resistance Level
- AQB $0.85
- ENVB $1.31
- Average True Range (ATR)
- AQB 0.07
- ENVB 0.07
- MACD
- AQB -0.01
- ENVB 0.02
- Stochastic Oscillator
- AQB 36.27
- ENVB 46.56
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.